LA-MeO, also known as lysergic acid ethyl-2-methoxyethylamide or as N-ethyl-N-(2-methoxyethyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). It is the O-methyl ether derivative of the LSD metabolite lysergic acid ethyl-2-hydroxyethylamide (LEO).
The drug shows high affinity for the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 4.0nM, 7.1nM, and 7.8nM, respectively). It acts as a potent partial agonist of the serotonin 5-HT<sub>2A</sub> receptor similarly to LSD, with an of 30.3nM and an of 29.6% (relative to 8.4nM and 22.4% in the case of LSD, respectively).
LA-MeO was first described in the scientific literature by Jason C. Parrish of the lab of David E. Nichols at Purdue University by 2007.